Introduction
Bladder cancer is the fourth most incident cancer in males and ninth most incident in females, with over 60 000 new cases expected to be diagnosed in 2006 (1) . Tobacco smoking (2) and occupational exposures (particularly including aromatic amines and polycyclic aromatic hydrocarbons) (3) are well known to contribute to the occurrence of bladder cancer. Drinking water arsenic exposure in highly exposed populations, exposure to hair dyes, chlorination by-products, individual fluid intake and diet also may play a role in genesis of this cancer (4) . Bladder cancer in the USA arises chiefly from the transitional cells of the bladder epithelium and most commonly presents as a noninvasive, papillary tumor that is readily treated through resection. However, $20% of incident cancers present as invasive disease (5) which have a 5-year survival rate of 30-50% (6, 7) . This pattern of disease incidence suggests that non-invasive and muscle-invasive disease arise from separate pathways, and that these pathways may be characterized by a distinct pattern of molecular alterations critical in the genesis of bladder tumors (5, 8) . Identification of the particular alterations and pathways that characterize these different forms of the disease holds great promise for application as clinical biomarkers of disease prognosis and patient survival. Additionally, molecular characterization of these distinct forms of the disease should offer a better understanding of the etiology of the disease; examining the patterns of molecular alterations associated with risk factors (specifically including exposure to bladder carcinogens) will illuminate their modes of action and role in disease occurrence.
The critical and causal role for epigenetic alterations in cancer is becoming increasingly understood. The most studied epigenetic alteration, DNA hypermethylation of the promoters of specific tumor suppressor genes, has been well established as an indicator of specific gene silencing, playing a crucial role in a variety of human cancers, including bladder cancer (9) . Indeed, a phenotype arising in a subset of tumors characterized by an increased propensity for methylation has been described in a variety of tumors; this is most clear in colorectal cancer (the CpG island methylator phenotype) (10, 11 ). Yet, the etiologies of gene-specific hypermethylation and the hypermethylator phenotype have been less well explored, and the clinical relevance of the phenotype (particularly across tumor types) remains unclear. In bladder cancer, we and others have linked DNA hypermethylation and inactivation of specific genes to poorer patient survival (12) (13) (14) and specific gene methylation to particular carcinogen exposures such as tobacco smoking and drinking water arsenic (15) . There is evidence that an increasing number of genes are subjected to hypermethylation silencing with increasing disease stage in bladder cancer (12, 16) , providing initial evidence for the existence of an underlying propensity for promoter hypermethylation, similar to that observed in colon cancer, that drives the clonal expansion of tumors and inactivation of critical pathways, potentially inducing the divergent forms of bladder cancer. We have previously reported that in bladder cancer, as well as lung cancer, head and neck squamous cell carcionoma and malignant pleural mesothelioma, that although there may be a propensity towards promoter hypermethylation in some tumors, it is not as clearly evident as in colorectal cancer (17) . Thus, appropriate statistical methodologies, as we have described (17, 18) , must be used to examine this data, particularly in order to examine the relationship between this propensity for methylation and its etiology or significance. This study is aimed at applying our IRT model methodologies, to examine 16 previously characterized (17) tumor suppressor gene promoters for hypermethylation, in a population-based case series of incident bladder cancers from the state of New Hampshire, which also includes detailed patient characteristics and exposure histories obtained from in-person interviews, expert pathologist reviewed clinical data on the tumors, and additional molecular characterization including TP53 status, and follow-up information on patient survival. This approach will allow for a detailed understanding of the etiology and clinical significance of these alterations that are considered central to the pathogenesis of bladder and other solid cancers.
Subjects and methods

Study population
Residents of New Hampshire aged 25-74 years, diagnosed from 1 July 1994 to 30 June 1998 were identified by the rapid reporting system of the New Hampshire State Cancer Registry and asked to participate in the study (19) . All study participants were consented under the appropriate institutional review board protocols. Study participants underwent a personal interview to obtain information on demographic traits and lifestyle factors, such as tobacco use (including frequency, duration and intensity of cigarette smoking). Follow-up data on overall patient survival were obtained through national death index query. Pathology material was complete from a total of 355 patients. Pathology reports and paraffin-embedded tumor specimens were requested from the treating physician/pathology laboratories. Bladder tumors were reviewed by the study pathologist (A.R.S.) and classified according to the 1973 and 2004 World Health Organization guidelines for bladder tumors. Additionally, the proportion of malignant cells in each sample was recorded for each sample, averaging 69% (median 80%). The final statistical analysis was performed on 331 tumors which had complete data on exposures, demographics and all laboratory analyses, including methylation at all loci and TP53 immunohistochemical (IHC) staining.
DNA extraction and sodium bisulfite modification
The study pathologist selected tumor sections with the greatest proportion of malignant tissue. Three 20 lM sections were cut from each formalin-fixed, paraffin-embedded tumor sample and the sections were transferred into microcentrifuge tubes. The paraffin was dissolved using Histochoice Clearing Agent (Sigma-Aldrich, St Louis, MO) followed by two washes with 100% ethanol and one wash with phosphate-buffered saline. The samples were then incubated in sodium dodecyl sulfate lysis solution (50 mM Tris-HCl, pH 8.1, 10 mM ethylenediaminetetraacetic acid, 1% sodium dodecyl sulfate) with proteinase K (Qiagen, Valencia, CA) overnight at 55°C. De-cross linking was performed by adding NaCl (final concentration 0.7 M) and incubating at 65°C for 4 h. DNA was recovered using the Wizard DNA clean-up kit (Promega, Madison, WI) according to the manufacturer's protocols. Sodium bisulfite modification of the DNA was performed using the EZ DNA Methylation Kit (Zymo Research, Orange, CA) following the manufacturer's protocol, with the addition of a 5 min initial incubation at 95°C prior to addition of the denaturation reagent. The de-cross-linking steps in the extraction as well as the 95°C incubation ensure more complete melting of the DNA and thus more complete sodium bisulfite conversion for these highly cross-linked formalin-fixed specimens.
Methylation-specific polymerase chain reaction
We have specifically chosen to utilize traditional methylation-specific polymerase chain reaction (PCR) for the analysis of promoter hypermethylation in these studies, as we have performed matched analysis between fresh-frozen and formalin-fixed, paraffin-embedded samples, and find the greatest concordance (.95%) for methylation detection using this method (data not shown). We have also previously examined potential biases in the sensitivity of using this assay against the relative quantitative Taqman-based methods (12) , and have seen no evidence for potential bias based on tumor quantity or tumor stage in the samples analyzed. Finally, this method allows for detection of a large number of genes from the limited DNA samples available on many of these tumors, with the advantage that it is standardized and potentially more widely available to investigators than the quantitative technologies which require realtime PCR systems.
Sodium bisulfite-modified DNA was used as the template for methylationspecific PCR as previously described (20) using primers specific for the methylated promoters of CDKN2A (20) , RASSF1A (21), APC (22), PYCARD (23), LAMC2 (24), SFRP1, SFRP2, SFRP4, SFRP5 (25), MGMT, DAPK, RARB, CDH1 (26), CDH13 (27), MLH1(28) and PRSS3 (29) . All methylation-specific PCRs are optimized to detect .5% methylated substrate in each sample. To control for the presence of modified DNA, primers specific to a modified region of the ACTB gene containing no CpG sites were used (30) . Modified circulating blood lymphocyte DNA (obtained from a control subject) and the same lymphocyte DNA completely methylated using SssI DNA methylase and modified by treatment with sodium bisulfite were used as the negative and positive controls, respectively, in each run.
This group of genes examined for promoter hypermethylation using this method have been previously shown to be correlated to transcriptional silencing of these genes. We also wished to examine the silencing of tumor suppressor genes involved in a variety of cellular processes and pathways, thereby not limiting the analysis to genes involved in a single pathway targeted for inactivation. The genes selected are known to be involved in processes including cell cycle control (CDKN2A, RASSF1A, APC), apoptosis (DAPK, PYCARD), extracellular interactions (LAMC2, PRSS3), transcriptional regulation (RARB), WNT signaling (SFRP family), cell-cell signaling (CDH1, CDH13) and DNA repair (MGMT, MLH1).
TP53 immunohistochemistry
The immunohistochemical detection of TP53 has been previously described (31) .
Statistical analysis
Since gene promoter hypermethylation does not occur as an independent event targeting individual genes, we applied a latent variable model. This is based upon the notion that fundamental relationships of interest can be characterized in terms of a small number of variables (conceptually perhaps viewed as biological parameters such as occult DNA polymorphisms or gene mutation/ amplification events that could drive a methylator phenotype), some of those being unobserved or latent (32) , and allows for the examination of the underlying propensity for promoter hypermethylation (33) . We then employed the IRT model (18, 34) , where binary responses on each of J items (gene promoters methylated) are related to a single continuous latent variable U, which can have a differential relationship on each item. Observed values, including those assessing exposure, demographics and clinical characteristics, can then be related to the latent variable through regression modeling. Using this methodology, we fit a model with 16 item responses (1 5 methylated, 0 5 not methylated) at the 16 gene loci. This model has been described in detail previously (17) .
We examined whether the underlying propensity for hypermethylation, characterized by U, would also be a predictor of the tumor's clinical phenotype. Our conceptual framework is depicted in Figure 1 , which shows a directed acyclic graph (35) To this end, we used the predictionsÛ in a second stage analysis where we employed a polytomous (multinomial) logistic regression (37) to model the association of tumor stage on hypermethylation and additional covariates. This approach is characterized as follows:
where S represents tumor stage, ranging across s 5 1 (non-invasive lowgrade), s 5 2 (non-invasive high-grade) and s 5 3 (invasive); W is a vector e. s and y could be ignored). In the case of propensity for promoter hypermethylation, m is not directly observed and must be measured via observables. In theory, y and s can (and should) both be used to measure m. However, s is distinct from y in that it includes multiple other sources of variation that add substantial noise relative to y when s serves as a surrogate for m. Additionally, as the probability calculation shows, the relationship between s and z must be correctly modeled if s and z are associated independently of m.
of covariates, including an intercept term and the latent variableÛ, and j s is a vector of corresponding regression coefficients with j 1 equal to the vector of zeros for the reference stage, non-invasive low-grade. Tumors classified as CIS were excluded from analysis due to the small number of tumor samples available. Finally, we examined the associations between propensity for hypermethylation, again characterized by U, and patient survival. In a second stage analysis, we used the predictions,Û, and employed a Cox proportional hazards model to examine the logarithm of the hazard of death as a linear function of covariates, includingÛ. To account for the error introduced by predicting U viâ U, we employed a bootstrap approach for estimating standard errors and biascorrected and accelerated (BcA) confidence intervals (CIs) (38) . All analyses were conducted in R version 2.1.1 (39), including custom software for the IRT model, available upon request.
To construct our IRT model, we used a stepwise selection combined with domain knowledge examining the effect of exposures on the latent methylation variable. Age and gender are included in the model as there have been reports of age-related methylation (40) and there is a well-established difference in the prevalence of bladder cancer by gender. We examined the effect of exposures which have been demonstrated to be associated with bladder cancer incidence including cigarette smoking and inorganic arsenic exposure (measured as toenail arsenic), both of which have been associated with gene-specific promoter hypermethylation in bladder cancer (12, 15) , as well as the possible association of occupational exposures [measured through work history questionnaires and classified dichotomously as high or low risk for occupational exposures (3)] and use of hair dyes with methylation silencing. Cigarette smoking was examined, as a variable comparing never, former and current smokers, as our previous work has suggested significant associations between current smoking and gene-specific hypermethylation (41) , and there is evidence that current smoking and longer smoking duration are associated with increased risk for bladder cancer (42) (43) (44) . As never and former smokers showed similar effect estimates for the latent trait, those groups we combined in the final model. We also examined models with smoking included as a continuous term representing duration (years smoked), intensity (cigarettes smoked per day) or packyears smoked, but found that models using the smoking status variable to better fit the data. We also examined in the model, the effect of alteration of TP53, both as mutation of the TP53 gene or as aberrant IHC staining intensity [scored on a four-point scale, and dichotomized in the model as 0 and 1 versus 2 and 3 (31)], as alterations of TP53 measured as altered IHC staining have been associated with specific gene-promoter hypermethylation (15) . The final model included age, gender, current smoking status and TP53 IHC staining as covariates in addition to the promoter hypermethylation status of the 16 genes examined.
Results
The demographics of the study population are shown in Table I and the prevalence of promoter hypermethylation of each of the genes examined is provided in Table II . Consistent with prior reports, we observed a correlation between promoter hypermethylation of various loci, prompting the use of a latent variable model to examine the characteristics of the propensity for methylation (supplementary Figure 1 is available at Carcinogenesis Online). We fit latent class models with 2-6 latent classes, as well as an IRT model [which essentially models an infinite number of latent classes as a continuous predictor (45)], and found the most parsimonious to be an IRT model that had a Bayesian Information Criterion value lower than the best (three class) latent class model (supplementary Table I is available at Carcinogenesis Online). Hence, we fit the IRT model to the described above to the 16 methylation item responses and included those covariates (age, gender, smoking status and TP53 IHC staining) that had a significant effect on the distribution of the latent methylation trait.
Results of the IRT model, including estimates of the slope and intercept coefficients for each of the genes examined, as well as the estimates of the slope coefficient for the covariate terms and their bootstrap-derived standard errors and BcA 95% CIs are given in Table III . The distribution of the modeled latent propensity for methylation is depicted (supplementary Figure 2 is available at Carcinogenesis Online) in order to better illustrate the spread of the latent variable for interpretation in later analyses. Overall, the model shows statistically significant differences among the IRT slopes (Wald P , 0.0001), suggesting this approach models the underlying propensity for methylation better than simply summing the number of methylated loci in each sample. All but two loci show significant sensitivity to the underlying latent methylation variable, with item response slopes ranging from 0.30 (CDKN2A) to 2.47 (SFRP2), implying that hypermethylation events do not occur independently. Promoter hypermethylation of MLH1 and CDH1 showed only borderline statistically significant sensitivity to the underlying latent variable. This may be related to their relative low prevalences of $3% each. Information on hair dye use was not available on one subject. b TP53 mutation was not available on eight subjects.
Characterization of methylation propensity in bladder cancer
This model suggests that age is related to the propensity for hypermethylation (overall Wald P value 5 0.002), with those patients in the highest quartile of age at diagnosis (.70 years) having a significant, positive association with a propensity for hypermethylation (Table III) . This association appears to be a local trend, as there was no appreciable trend in age among the three lower age groups; those patients in the lower quartiles had no significant or increasing estimates of their mean effect on the underlying latent variable. Patients of the male gender also showed a significant positive association with the hypermethylation latent trait (estimate 0.41, 95% BcA CI 0.03, 0.75). Tumors with altered TP53 protein, defined as intense IHC staining (2 or 3þ) versus low or no staining, also showed a significant positive relationship with promoter hypermethylation. Consistent with previous reports about gene-specific hypermethylation events associated with tobacco smoking, this model suggests that current smokers, compared with never or former smokers, also have an increased propensity for promoter hypermethylation. If modeled separately, never and former smokers had similar estimates and were collapsed into a single category. Current smoking had a latent trait mean effect of 0.43 (95% BcA CI 0.10, 0.70) and performed better in the model than when we used duration (years of smoking), intensity (packs of cigarettes smoked per day) or pack-years smoked.
Our group and others have previously reported associations between gene-specific promoter hypermethylation as well as TP53 alteration and clinical features of the disease, particularly tumor stage. Thus, we asked whether the underlying propensity for hypermethylation also would be a predictor of the tumor's clinical phenotype. This was done by a polytomous logistic regression model (2), modeling disease stage (low stage/low grade, low stage/high grade and high stage) with the latent trait term as well as patient age, gender and TP53 IHC status (known to be important in prediction of disease stage or as possible confounders). Overall, neither age nor gender demonstrated a statistically significant association with stage. As has been previously reported, moderate to intense TP53 IHC staining was significantly associated with invasive stage disease, with an odds ratio of 4.3 (95% BcA CI 2.2, 9.2) for invasive stage disease compared with non-invasive/low-grade disease assuming the tumors were not of other disease stages. Interestingly, TP53 IHC was not correlated to non-invasive/high-grade status after adjusting for other factors. The hypermethylation latent trait was statistically significantly associated with both non-invasive/high-grade and invasive stages of disease (Table IV) . For each one unit increase in the methylation latent trait, the odds of being a non-invasive/high-grade tumor increased by 2.1-fold (95% BcA CI 1.1, 3.5) compared with non-invasive/low-grade tumors, assuming the tumor was in either of those categories. The odds of being an invasive stage tumor increased by 2.9-fold (95% BcA CI 2.0, 4.4) compared with non-invasive/low-grade tumors, assuming the tumor was in either of those categories.
We also used a Cox's proportional hazards model, predicting the outcome of death, with the hypermethylation latent variableÛ as a predictor, and controlling again for patient age and gender, as well as TP53 IHC staining [which we have shown to be previously independently associated with patient survival (12) ]. The results of this model are presented in Table V . We have specifically examined the relationship between the methylation latent trait and survival without tumor stage in the model, as our previous polytomous regression analysis suggests that these variables are highly correlated and biologically we believe that the propensity for promoter hypermethylation and stage exist in the same causal pathway. Thus, including both in the model would reduce power to see the associations of each with patient survival. In the model, every unit increase in the methylation latent trait increased the instantaneous hazard of death by 1.3 (95% BcA CI 1.0, 1.6, P , 0.02). Interestingly, TP53 IHC staining defined as 2 or 3þ compared with low or no IHC positivity no longer, had a significant relationship with patient survival time when controlling for promoter hypermethylation. As expected, age and patient gender remains significant predictors of poor prognosis.
Discussion
Epigenetic alterations, particularly, promoter hypermethylation-associated gene silencing, are known to be critically important in carcinogenesis, although the etiology and mechanism of gene-specific targeting for silencing remain unclear. Further, the silenced genes and pathways in bladder cancers span the range of cellular processes, interact in many cellular networks driving development and growth, and do not occur as independent events. Hence, we have studied the etiology and significance of promoter hypermethylation in bladder cancer by employing a large, population-based case series design, capturing the entire range of incident disease. We have taken cues from the field of systems biology in the analysis of these results, utilizing a statistical approach that specifically does not require assumptions of independence for the epigenetic events or the existence of a defined dichotomous phenotype and which allows for the study of the impact of methylation as a latent variable in a regression framework, consistent with the biological notion of effect modification.
In examining methylation as a latent variable, we observed a significant relationship with patient age at diagnosis, with those patients in the highest quartile of age at diagnosis showing the largest association with the methylation latent trait. A similar relationship has been observed in specific genes in aging colon tissue, although this has been thought to be limited to specific gene promoters (10, 46, 47) . Our data suggest that older bladder cancer patients have an increased propensity for more general hypermethylation, a result consistent with reports examining specific genes in bladder cancer (40) . This propensity for overall hypermethylation may be related to the aging process, to increased DNA damage and genomic instability related to aging or to an increased duration of carcinogen exposure, although we saw no specific effects, for example, of a relationship between the methylation latent trait and duration of cigarette smoking. We also observe a significant relationship with altered TP53 protein. TP53 pathway inactivation may be contributing to increased promoter hypermethylation as a response to the increasing genomic instability and recombination events leading to alterations in chromatin structure and thus DNA methylation related.
Similar to previous reports in bladder cancer linking current cigarette smoking at the time of diagnosis and gene-specific promoter hypermethylation events (12, 15) , we observed a significantly increased propensity for promoter hypermethylation in current smokers compared with never or former smokers. This adds to a growing body of evidence in a number of malignancies that cigarette smoke is not only a mutagenic carcinogen but also is associated with the genesis of epigenetic alterations in cancer (48) (49) (50) (51) . Our data, showing current smoking, rather than duration or intensity of smoking, to most alter promoter methylation suggest that the recency of exposure or the continuous exposure of the developing tumor to tobacco-related carcinogens may be critical in driving or selecting clones harboring epigenetic alterations. Indeed, tumors in never or former smoking patients will be characterized by different molecular alterations driven by different selective pressures. Importantly, these data suggest that the propensity for methylation requires continual selection pressure at the cellular level and might be positively impacted by changes in lifestyle.
The initial IRT model also suggests that men have an increased propensity for promoter hypermethylation compared with women. Men have a 3-to 6-fold higher incidence of bladder cancer than women which cannot be accounted for by differences in carcinogen exposure (52, 53) . Our results raise the possibility of a biological difference between tumors of men and women, similar to that posited in a study of lung cancer. Lai et al. (54) observed an association of gene hypermethylation with gender and their data suggested that exposure of lung cancer cell lines to b-estradiol could reverse promoter hypermethylation-induced gene silencing. However, additional evidence connecting hormones and protection or promotion of gene promoter hypermethylation is lacking. In the case of bladder cancer, the anatomical differences between men and women might also play a role. Consistent with the concept that continued exposure and cell turnover are crucial for selection of clones with silenced genes (e.g. current smoking and age), it is tempting to speculate that chronic exposure of the epithelium to urinary carcinogens due to an inability of older men to completely void (consequent to prostatic hyperplasia or other urinary tract conditions) provides the needed selection pressure. Frequency of urination is associated with bladder cancer, with greater frequency and greater fluid intake being protective for the disease (55) (56) (57) . More specific examination of voiding frequency and volume would be necessary to more thoroughly examine this potential link.
Compared with low-stage/low-grade tumors, we found an increased methylation propensity to be associated with greater odds of being either higher grade or higher stage, while TP53 inactivation predicted only higher stage (invasive) disease. Promoter hypermethylation, therefore, may be a critical factor in defining both higher grade, non-invasive disease, as well as predicting invasive disease. Like Blaveri et al. (58) who showed that gross genomic instability was lower in invasive stage disease than in non-invasive/high-grade disease, our data suggest that, in invasive disease, epigenetic alteration may be the dominant mode of inactivation of tumor suppressor genes. In non-invasive disease, genetic alterations (resultant of instability) characterized by chromosomal loss, transition and amplification may predominate.
Consistent with the forgoing, promoter hypermethylation modeled as a latent trait was associated with patient survival. As we believe the propensity for methylation and stage to be in the same causal pathway for survival, we employed a model examining the effect of the methylation latent trait controlled for age, gender and TP53 IHC staining, but not stage. In this model, the methylation latent trait was significantly associated with patient survival. If stage is included in the model, the hazard ratio (HR) for both stage and the modelled latent trait would be non-significant, and the HR for both reduced. Taken together with the multivariate model linking methylation propensity to tumor stage, these results imply that methylation is causally related to tumor stage and thus part of the causal pathway of patient survival.
We have previously shown that TP53 alteration, as demonstrated by intense IHC staining was significantly associated with invasive stage tumors and patient survival (31) . In the current analysis, TP53 IHC staining was not a significant predictor of survival, but remained a significant predictor of invasive stage tumors, whereas the propensity for hypermethylation is associated with both non-invasive/highgrade and invasive stage tumors as well as with patient survival. This suggests distinct clinical phenotypes associated with these alterations, in that TP53 staining likely strongly predicts all invasive stage dis- Characterization of methylation propensity in bladder cancer ease, similar to the way in which mutation of the FGFR3 gene predicts non-invasive disease, specifically (59, 60) . At the same time, the propensity for promoter hypermethylation may specifically predict the most aggressive and deadly types of bladder cancer, regardless of their morphology and staging at diagnosis. This very strongly suggests that clinical prospective studies closely examine the utility of the methylation propensity (rather than single gene silencing) as a marker of patient outcome. Overall, our results suggest an etiology for both promoter hypermethylation as well as for the genesis of the crucial epigenetic alterations that create a tumor phenotype and alter patient outcome. Our model indicates that continuous tobacco carcinogen exposure, in combination with increasing age, and male gender, drives and enhances the selection of epigenetically altered cells. Additionally, these models show that the invasive form of this disease is characterized by a predominance of epigenetic events, whereas the non-invasive forms, consistent with previous reports, are characterized by gross genomic instability. Thus, promoter hypermethylation profiling of tumor specimens may help to define those more probably to progress and lead to increased mortality. It may also delineate patients who would benefit from more radical treatment or more careful follow-up.
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